Allogeneic (Universal) CAR-γδ T-Cells with Superior Anti-Tumor Effectiveness and Safety Profile

SenlangBio’s Next Generation Universal/Allogeneic (“Off-The-Shelf”) CAR Therapy Utilizes γδ T-Cells

T lymphocytes bearing the CD3 antigen can be split into αβ or γδ T-cells based on their heterodimeric receptor chain. Senlang’s allogeneic CAR-T therapy utilizes γδ cells.

Disadvantages of Allogeneic CAR-T Based on αβ T-Cells

  • Gene editing is required to knock out the αβ TCR or TCR signaling needs to be suppressed. Both of these processes are complicated, expensive, and potentially risky.
  • Gene editing can potentially result in off-target effects. Cellectis recently announced that the FDA placed its MELANI-01 trial for multiple myeloma patients on clinical hold following the death of a patient using their UCARTCS1A allogeneic CAR-T therapy

Advantages of Allogeneic CAR-T Based on γδ T-Cells

  • Great candidate for off-the-shelf CAR-T since the antigen recognition is not MHC restricted, meaning donor compatibility is not required.
  • γδ T-cells are pre-programmed to target cancerous cells and do not cause graft versus host reaction (GvHD)
  • γδ T-cells are part of both adaptive immunity and innate immunity responses
  • γδ T-cells express various NK cell receptors

Senl_GDUCARxxx (undisclosed target)

Breakthrough in Treatment of Myeloid Malignancies

  • Universal (“off-the-shelf”) CAR-γδ T targeting a specific myeloid onco-antigen
  • For the treatment of relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
  • Senl_GDUCARxxx (undisclosed target) can potentially overcome the poor results of CAR-T against myeloid malignancy (AML/MDS):
    • Highly purified γδ T cells (> 99%), almost without αβ T-cells contamination
    • Large-scale expansion of γδ T-cells (>5,000 folds) from cord blood

Senl_GDSTCLD18

  • Universal (“off-the-shelf”) CAR-γδT targeting a specific solid tumor antigen
  • For the treatment of gastric, pancreatic cancers and potentially other solid tumors
  • SenlangBio’s γδ T technology platform can potentially overcome the poor results from conventional CAR-T against solid tumors:
  • Highly purified γδ T cells (> 99%), almost without αβ T-cells contamination
    • Large-scale expansion of γδ T-cells (5,000 folds) from cord blood
    • High transduction efficiency; better tumor homing capability
    • Improved durability in retaining viability and functional activity